296 related articles for article (PubMed ID: 25362149)
21. HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.
Hu T; Schreiter FC; Bagchi RA; Tatman PD; Hannink M; McKinsey TA
J Biol Chem; 2019 May; 294(21):8640-8652. PubMed ID: 30962285
[TBL] [Abstract][Full Text] [Related]
22. [The mechanism underlying histone deacetylases regulating cardiac hypertrophy].
Ren L; Wu XS; Li YQ
Yi Chuan; 2020 Jun; 42(6):536-547. PubMed ID: 32694112
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression.
Morales CR; Li DL; Pedrozo Z; May HI; Jiang N; Kyrychenko V; Cho GW; Kim SY; Wang ZV; Rotter D; Rothermel BA; Schneider JW; Lavandero S; Gillette TG; Hill JA
Sci Signal; 2016 Apr; 9(422):ra34. PubMed ID: 27048565
[TBL] [Abstract][Full Text] [Related]
24. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
[TBL] [Abstract][Full Text] [Related]
25. PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy.
Ha CH; Kim JY; Zhao J; Wang W; Jhun BS; Wong C; Jin ZG
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15467-72. PubMed ID: 20716686
[TBL] [Abstract][Full Text] [Related]
26. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
27. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5.
Vega RB; Harrison BC; Meadows E; Roberts CR; Papst PJ; Olson EN; McKinsey TA
Mol Cell Biol; 2004 Oct; 24(19):8374-85. PubMed ID: 15367659
[TBL] [Abstract][Full Text] [Related]
28. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Lemon DD; Horn TR; Cavasin MA; Jeong MY; Haubold KW; Long CS; Irwin DC; McCune SA; Chung E; Leinwand LA; McKinsey TA
J Mol Cell Cardiol; 2011 Jul; 51(1):41-50. PubMed ID: 21539845
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Raghunathan S; Goyal RK; Patel BM
Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
[TBL] [Abstract][Full Text] [Related]
30. Myofibril growth during cardiac hypertrophy is regulated through dual phosphorylation and acetylation of the actin capping protein CapZ.
Lin YH; Warren CM; Li J; McKinsey TA; Russell B
Cell Signal; 2016 Aug; 28(8):1015-24. PubMed ID: 27185186
[TBL] [Abstract][Full Text] [Related]
31. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
32. Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.
Eom GH; Kook H
BMB Rep; 2015 Mar; 48(3):131-8. PubMed ID: 25388210
[TBL] [Abstract][Full Text] [Related]
33. HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy.
Hamamori Y; Schneider MD
J Clin Invest; 2003 Sep; 112(6):824-6. PubMed ID: 12975465
[TBL] [Abstract][Full Text] [Related]
34. Non-sirtuin histone deacetylases in the control of cardiac aging.
Ferguson BS; McKinsey TA
J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
[TBL] [Abstract][Full Text] [Related]
35. Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes.
Blakeslee WW; Lin YH; Stratton MS; Tatman PD; Hu T; Ferguson BS; McKinsey TA
J Mol Cell Cardiol; 2017 Nov; 112():74-82. PubMed ID: 28886967
[TBL] [Abstract][Full Text] [Related]
36. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart.
Habibian J; Ferguson BS
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597863
[TBL] [Abstract][Full Text] [Related]
37. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors.
Grégoire S; Yang XJ
Mol Cell Biol; 2005 Mar; 25(6):2273-87. PubMed ID: 15743823
[TBL] [Abstract][Full Text] [Related]
38. Approaches for Studying the Subcellular Localization, Interactions, and Regulation of Histone Deacetylase 5 (HDAC5).
Guise AJ; Cristea IM
Methods Mol Biol; 2016; 1436():47-84. PubMed ID: 27246208
[TBL] [Abstract][Full Text] [Related]
39. Heart failure: the pivotal role of histone deacetylases.
Hewitson R; Dargan J; Collis D; Green A; Moorjani N; Ohri S; Townsend PA
Int J Biochem Cell Biol; 2013 Feb; 45(2):448-53. PubMed ID: 23178536
[TBL] [Abstract][Full Text] [Related]
40. CAMTA in cardiac hypertrophy.
Schwartz RJ; Schneider MD
Cell; 2006 May; 125(3):427-9. PubMed ID: 16678087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
